Endocrine hypertension: Then and now

Endocrine Practice

Volumn 16, Issue 5, 2010, Pages 888-902

  Young Jr , William F ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EPLERENONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADRENAL CORTEX ADENOMA; ADRENAL GLAND; ADRENALECTOMY; ALDOSTERONE PRODUCING ADENOMA; BLOOD PRESSURE MONITORING; ENVIRONMENTAL FACTOR; HUMAN; HYPERTENSION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; REVIEW; TUMOR LOCALIZATION;

ADRENAL GLAND NEOPLASMS; ADULT; ENDOCRINE SYSTEM; ENDOCRINE SYSTEM DISEASES; ENDOCRINOLOGY; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPERTENSION; PHEOCHROMOCYTOMA;

EID: 78149310717     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP10205.RA     Document Type: Review

References (164)

1. Mayo CH. Paroxysmal hypertension with tumor of retroperitoneal nerve. JAMA. 1927;89:1047-1050.
2. Saegesser F. César Roux (1857-1934) and his times [article in French]. Rev Med Suisse Romande. 1984;104:403-464.
3. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-17.
4. van Heerden JA. First encounters with pheochromocytoma. The story of Mother Joachim. Am J Surg. 1982;144:277-279.
5. Kvale WF, Roth, GM, Clagett, OT, Dockerty, MB. Headache and paroxysmal hypertension: Observations before and after the surgical removal of a pheochromocytoma. Surg Clin of North Am. 1944:922-933.
6. Roth GM, Flock EV, Kvale WF, Waugh JM, Ogg J. Pharmacologic and chemical tests as an aid in the diagnosis of pheochromocytoma. Circulation. 1960;21:769-778.
7. Gifford RW Jr, Roth GM, Kvale WF. Evaluation of new adrenolytic drug (regitine) as test for pheochromocytoma. J Am Med Assoc. 1952;149:1628-1634.
8. Grimson KS, Longino FH. Treatment of a patient with a pheochromocytoma; Use of an adrenolytic drug before and during operation. J Am Med Assoc. 1949;140:1273.
9. lenders JW, Pacak K, Huynh TT, et al. Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab. 2010;95:238-245.
10. young WF Jr, Maddox DE. Spells: In search of a cause. Mayo Clin Proc. 1995;70:757-765.
11. Oliver G, Schafer EA. Physiological effects of extracts of suprarenal capsules. J Physiol. 1895;18:230.
12. Stolz F. Ueber adrenalin und alkylamino-acetobrenzcatechin. Ber Deutsch Chem Ges. 1904;37:4149.
13. Engel A, von Euler US. Diagnostic value of increased urinary output of pheochromocytoma. Lancet. 1950;2:387.
14. Lund A. Fluorimetric determination of adrenaline in blood; a new sensitive and specifc method. Acta Pharmacol Toxicol (Copenh). 1949;5:231-247.
15. Weil-Malherbe H, Bone AD. The chemical estimation of adrenaline-like substances in blood. Biochem J. 1952;51:311-318.
16. Von Euler US, Floding I. Fluorimetric estimation of noradrenaline and adrenaline in urine. Acta Physiol Scand Suppl. 1955;33:57-62.
17. Armstrong MD, McMillan A, Shaw KN. 3-Methyoxy-4hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine. Biochem Biophys Acta. 1957;25:422-423.
18. Sheps SG, Tyce GM, Flock EV, Maher FT. Current experience in the diagnosis of pheochromocytoma. Circulation. 1966;34:473-483.
19. Pisano JJ. A simple analysis for normetanephrine and metanephrine in urine. Clin Chim Acta. 1960;5:406-414.
20. Moyer TP, Jiang NS, Tyce GM, Sheps SG. Analysis for urinary catecholamines by liquid chromatography with amperometric detection: methodology and clinical interpretation of results. Clin Chem. 1979;25:256-263.
21. lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem. 1993;39:97-103.
22. lenders JW, Keiser HR, Goldstein DS, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med. 1995;123:101-109.
23. lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: Which test is best? JAMA. 2002;287:1427-1434.
24. Taylor RL, Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem. 2002;48:533-539.
25. lagerstedt SA, O'Kane DJ, Singh RJ. Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem. 2004;50:603-611.
26. Singh RJ. Advances in metanephrine testing for the diagnosis of pheochromocytoma. Clin Lab Med. 2004;24:85-103.
27. Sawka AM, Jaeschke R, Singh RJ, young WF Jr. A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;88:553-558.
28. von Euler US. Increased urinary excretion of noradrenaline and adrenaline in cases of pheochromocytoma. Ann Surg. 1951;134:929-933.
29. Snyder CH, Rutledge LJ. Pheochromocytoma: Localization by aortography. Pediatrics. 1955;15:312-316.
30. Saltz NJ, Luttwak EM, Schwartz A, Goldberg GM. Danger of aortography in the localization of pheochromocytoma. Ann Surg. 1956;144:118-123.
31. Pendergrass HP, Tristan TA, Blakemore WS, Sellers AM, Jannetta PJ, Murphy JJ. Roentgen technics in the diagnosis and localization of pheochromocytoma. Radiology. 1962;78:725-737.
32. Crout JR, Sjoerdsma A. Catecholamines in the localization of pheochromocytoma. Circulation. 1960;22:516-525.
33. Graham JB. Pheochromocytoma and hypertension; An analysis of 207 cases. Int Abstr Surg. 1951;92:105-121.
34. Hardy JD, Carter T, Turner MD. Catechol amine metabolism: Peripheral plasma levels of epinephrine (E) and norepinephrine (NE) during laparotomy under different types of anesthesia in dogs, during operation in man (including adrenal vein sampling), and before and following resection of a pheochromocytoma associated with von Recklinghausen's neurofbromatosis. Ann Surg. 1959;150:666-683.
35. Mahoney EM, Friend DG, Dexter L, Harrison JH. Localization of (adrenal and extra-adrenal) pheochromocytoma by vena caval blood sampling. Surg Forum. 1963;14:495-496.
36. Mahoney EM, Crocker DW, Friend DG, Dexter L, Skillman JJ, Harrison JH. Adrenal and extra-adrenal pheochromocytomas: Localization by vena cava sampling and observations on renal juxtaglomerular apparatus. J Urol. 1972;108:4-8.
37. Harrison TS, Freier DT. Pitfalls in the technique and interpretation of regional venous sampling for localizing pheochromocytoma. Surg Clin North Am. 1974;54:339-347.
38. Pickering RS, Hartman GW, Weeks RE, Sheps SG, Hattery RR. Excretory urographic localization of adrenal cortical tumors and pheochromocytomas. Radiology. 1975;114:345-349.
39. Stewart BH, Bravo EL, Haaga J, Meaney TF, Tarazi R. Localization of pheochromocytoma by computed tomography. N Engl J Med. 1978;299:460-461.
40. Ganguly A, Pratt JH, Yune HY, Grim CE, Weinberger MH. Detection of adrenal tumors by computerized tomographic scan in endocrine hypertension. Arch Intern Med. 1979;139:589-590.
41. Laursen K, Damgaard-Pedersen K. CT for pheochromocytoma diagnosis. AJR Am J Roentgenol. 1980;134:277-280.
42. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981;305:12-17.
43. lynn MD, Shapiro B, Sisson JC, et al. Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication. J Nucl Med. 1984;25:436-440.
44. Moon KL, Jr., Hricak H, Crooks LE, et al. Nuclear magnetic resonance imaging of the adrenal gland: a preliminary report. Radiology. 1983;147:155-160.
45. Davis PL, Hricak H, Bradley WG Jr. Magnetic resonance imaging of the adrenal glands. Radiol Clin North Am. 1984;22:891-895.
46. Fink IJ, Reinig JW, Dwyer AJ, Doppman JL, Linehan WM, Keiser HR. MR imaging of pheochromocytomas. J Comput Assist Tomogr. 1985;9:454-458.
47. Greenberg M, Moawad AH, Wieties BM, et al. Extraadrenal pheochromocytoma: Detection during pregnancy using MR imaging. Radiology. 1986;161:475-476.
48. Shulkin BL, Wieland DM, Schwaiger M, et al. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med. 1992;33; 1125-1131.
49. Shulkin BL, Koeppe RA, Francis IR, Deeb GM, Lloyd RV, Thompson NW. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: Localization with PET and administration of FDG. Radiology. 1993;186:711-715.
50. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: Imaging with 2-[fuorine-18]fuoro-2-deoxy-D-glucose PET. Radiology. 1999;212:35-41.
51. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001;38:6-8.
52. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: Detection with 18F DOPA whole body PET-initial results. Radiology. 2002;222:507-512.
53. Klein RD, Lloyd RV, young WF. Hereditary Paraganglioma-Pheochromocytoma Syndromes. In: Pagon RA, Bird TC, Dolan CR, Stephens K, eds. GeneReviews. Seattle, WA: University of Washington, Seattle, 2009.
54. Gifford RW Jr, Kvale WF, Maher FT, Roth GM, Priestley JT. Clinical features, diagnosis and treatment of pheochromocytoma: Review of 76 cases. Mayo Clin Proc. 1964;39:281-302.
55. Manning PC Jr, Molnar GD, Black BM, Priestley JT, Woolner LB. Pheochromocytoma, hyperparathyroidism, and thyroid carcinoma occurring coincidentally: Report of a case. N Engl J Med. 1963;268:68-72.
56. Schimke RN, Hartmann WH. Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity. Ann Intern Med. 1965;63:1027-1039.
57. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: Multiple endocrine neoplasia, type 2. Medicine (Baltimore). 1968;47:371-409.
58. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458-460.
59. Collins ET. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably primarily retinal, affecting both eyes). Trans Ophthal Soc U. K. 1894;14:141-149.
60. von Hippel E. Ueber eine sehr seltene Erkrankung der Netzhaut. Albrecht von Graefes Arch. Ophthal. 1904;59:83-106.
61. Lindau A. Zur Frage der Angiomatosis Retinae und Ihrer Hirncomplikation. Acta Ophthal. 1927;4:193-226.
62. Melmon KL, Rosen SW. Lindau's disease. Review of the literature and study of a large kindred. Am J Med. 1964;36:595-617.
63. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317-1320.
64. Akenside M. Observations on cancers. Medical Transactions Royal College of Physicians of London. 1768;1:64-92.
65. Smith RW. A Treatise on the Pathology, Diagnosis and Treatment of Neuroma, Dublin: Hodges and Smith, 1849.
66. von Recklinghausen FD. Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. Berlin: A. Hirschwald, 1882.
67. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofbromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181-186.
68. Wallace MR, Andersen LB, Saulino AM, Gregory PE, Glover TW, Collins FS. A de novo Alu insertion results in neurofibromatosis type 1. Nature. 1991;353:864-866.
69. Bartels J. De tumoren van het glomus jugulare, Thesis Groningen, Netherlands, 1949.
70. Kroll AJ, Alexander B, Cochios F, Pechet L. Hereditary defciencies of clotting factors VII and X associated with carotid-body tumors. N Engl J Med. 1964;270:6-13.
71. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848-851.
72. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69:49-54.
73. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268-270.
74. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for favination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;325:1139-1142.
75. Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42:229-233.
76. Remine WH, Chong GC, Van Heerden JA, Sheps SG, Harrison EG Jr. Current management of pheochromocytoma. Ann Surg. 1974;179:740-748.
77. Orchard T, Grant CS, van Heerden JA, Weaver A. Pheochromocytoma- continuing evolution of surgical therapy. Surgery. 1993;114:1153-1158; discussion 1158-1159.
78. Gagner M, Lacroix A, Bolte E. Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. N Engl J Med. 1992;327:1033.
79. Thompson GB, Grant CS, van Heerden JA, et al. Laparoscopic versus open posterior adrenalectomy: A case-control study of 100 patients. Surgery. 1997;122:1132-1136.
80. Jaroszewski DE, Tessier DJ, Schlinkert RT, et al. Laparoscopic adrenalectomy for pheochromocytoma. Mayo Clin Proc. 2003;78:1501-1504.
81. Walz MK, Alesina PF, Wenger FA, et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: Results of 161 tumors in 126 patients. World J Surg. 2006;30:899-908.
82. Motta-Ramirez GA, Remer EM, Herts BR, Gill IS, Hamrahian AH. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;185:684-688.
83. young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:601-610.
84. Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: Data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161:355-361.
85. Perry CG, Sawka AM, Singh R, Thabane L, Bajnarek J, Young WF Jr. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf). 2007;66:703-708.
86. Kinney MA, Warner ME, vanHeerden JA, et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg. 2000;91:1118-1123.
87. Brown ML, Zayas GE, Abel MD, Young WF Jr, Schaff HV. Mediastinal paragangliomas: The mayo clinic experience. Ann Thorac Surg. 2008;86:946-951.
88. Young WF Jr. Paragangliomas: Clinical overview. Ann N Y Acad Sci. 2006;1073:21-29.
89. Conn JW. Electrolyte composition of sweat; clinical implications as an index of adrenal cortical function. Arch Intern Med (Chic). 1949;83:416-428.
90. Grundy HM, Simpson SA, Tait JF. Isolation of a highly active mineralocorticoid from beef adrenal extract. Nature. 1952;169:795-796.
91. Gaunt R, Gordon AS, Renzi AA, Padawer J, Fruhman GJ, Gilman M. Biological studies with electrocortin (aldosterone). Endocrinology. 1954;55:236-241.
92. Gittler RD, Fajans SS. Primary aldosteronism (Conn's syndrome). J Clin Endocrinol Metab. 1995;80:3438-3441.
93. Conn JW, Knopf, RF, Nesbit, RM. Clinical characteristics of primary aldosteronism from analysis of 145 cases. Am J Surg. 1964;107:159-172.
94. Conn JW. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. J Am Med Assoc. 1964;190:222-225.
95. Fishman LM, Kuchel O, Liddle GW, Michelakis AM, Gordon RD, Chick WT. Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA. 1968;205:497-502.
96. Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med. 1967;66:1079-1090.
97. Conn JW. The evolution of primary aldosteronism: 1954-1967. Harvey Lect. 1966;62:257-291.
98. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-1050.
99. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281100.
100. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1, 125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
101. Clark I. A colorimetric reaction for the estimation of cortisone, hydrocortisone, aldosterone and related steroids. Nature. 1955;175:123-124.
102. Axelrad BJ, Cates JE, Johnson BB, Luetscher JA Jr. Aldosterone in urine of normal man and of patients with oedema; its increased recovery after hydrolysis with acid and with beta-glucuronidase. Br Med J. 1955;1:196-199.
103. Conn JW. Evolution of primary aldosteronism as a highly specifc clinical entity. J Am Med Assoc. 1960;172:1650-1653.
104. Boucher R, Veyrat R, De Champlain J, Genest J. New procedures for measurement of human plasma angiotensin and renin activity levels. Can Med Assoc J. 1964;90:194-201.
105. Conn JW, Cohen EL, Rovner DR. Suppression of plasma renin activity in primary aldosteronism. JAMA. 1964;190:213-221.
106. Carey RM. Screening for surgically correctable hypertension caused by primary aldosteronism. Arch Intern Med. 1981;141:1594.
107. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141:1589-1593.
108. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993;153:2125-2129.
109. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: Diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51:386-394.
110. young WF. Primary aldosteronism: Renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66:607-618.
111. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699-705.
112. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofeld S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18:805-812.
113. Bayard F, Beitins IZ, Kowarski A, Migeon CJ. Measurement of plasma aldosterone by radioimmunoassay. J Clin Endocrinol Metab. 1970;31:1-6.
114. Cope CL, loizou S. Simplification of urinary aldosterone measurement by radioimmunoassay. J Clin Pathol. 1973;26:628-634.
115. Fredline VF, Taylor PJ, Dodds HM, Johnson AG. A reference method for the analysis of aldosterone in blood by high-performance liquid chromatography- atmospheric pressure chemical ionization-tandem mass spectrometry. Anal Biochem. 1997;252:308-313.
116. Turpeinen U, Hamalainen E, Stenman UH. Determination of aldosterone in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862:113-118.
117. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to- plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am. 2002;31:619-632, xi.
118. Rossi GP, Seccia TM, Palumbo G, et al. Within-patient reproducibility of the aldosterone: Renin ratio in primary aldosteronism. Hypertension. 2010;55:83-89.
119. Young WF Jr. Primary aldosteronism: diagnosis. In: Mansoor GA, ed. Hypertension: Clinical Presentation, Diagnosis, and Treatment. Totowa, NJ: Humana Press, 2004:119-137.
120. Conn JW, Rovner DR, Cohen EL, Bookstein JJ, Cerny JC, lucas CP. Preoperative diagnosis of primary aldosteronism, including a comparison of operative findings and preoperative tumor localization by adrenal phlebography. Arch Intern Med. 1969;123:113-123.
121. Melby JC, Spark RF, Dale SL, Egdahl RH, Kahn PC. Diagnosis and localization of aldosterone-producing adenomas by adrenal-vein cateterization. N Engl J Med. 1967;277:1050-1056.
122. Biglieri EG, Schambelan M, Slaton PE, Stockigt JR. The intercurrent hypertension of primary aldosteronism. Circ Res. 1970;27:195-202.
123. Ferriss JB, Brown JJ, Fraser R, et al. Hypertension with aldosterone excess and low plasma-renin: preoperative distinction between patients with and without adrenocortical tumour. Lancet. 1970;2:995-1000.
124. Conn JW, Beierwaltes WH, Lieberman LM, et al. Primary aldosteronism: Preoperative tumor visualization by scintillation scanning. J Clin Endocrinol Metab. 1971;33:713-716.
125. Sarkar SD, Cohen EL, Beierwaltes WH, Ice RD, Cooper R, Gold EN. A new and superior adrenal imaging agent, 131I-6beta-iodomethyl-19-nor-cholesterol (NP-59): Evaluation in humans. J Clin Endocrinol Metab. 1977;45:353-362.
126. Hogan MJ, McRae J, Schambelan M, Biglieri EG. Location of aldosterone-producing adenomas with 131I-19-iodocholesterol. N Engl J Med. 1976;294:410-414.
127. Nomura K, Kusakabe K, Maki M, Ito Y, Aiba M, Demura H. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. J Clin Endocrinol Metab. 1990;71:825-830.
128. Ganguly A, Dowdy AJ, luetscher JA, Melada GA. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab. 1973;36:401-404.
129. Young WF Jr, Klee GG. Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am. 1988;17:367-395.
130. Biglieri EG, Schambelan M. The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism. J Clin Endocrinol Metab. 1979;49:87-91.
131. Schaner EG, Dunnick NR, Doppman JL, Strott CA, Gill JR Jr, Javadpour N. Adrenal cortical tumors with low attenuation coefficients: a pitfall in computed tomography diagnosis. J Comput Assist Tomogr. 1978;2:11-15.
132. Ganguly A, Pratt JH, Yune HY, Grim CC, Weinberger MH. Computerized tomographic scanning and primary aldosteronism. N Engl J Med. 1979;301:558.
133. Vetter H, Brecht G, Fischer M, et al. Lateralization procedures in primary aldosteronism. Klin Wochenschr. 1980;58:1135-1141.
134. White EA, Schambelan M, Rost CR, Biglieri EG, Moss AA, Korobkin M. Use of computed tomography in diagnosing the cause of primary aldosteronism. N Engl J Med. 1980;303:1503-1507.
135. Doppman JL, Gill JR Jr. Hyperaldosteronism: Sampling the adrenal veins. Radiology. 1996;198:309-312.
136. Doppman JL, Gill JR Jr, Miller DL, et al. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: Reliability of CT. Radiology. 1992;184:677-682.
137. Dunnick NR, Doppman JL, Mills SR, Gill JR Jr. Preoperative diagnosis and localization of aldosteronomas by measurement of corticosteroids in adrenal venous blood. Radiology. 1979;133:331-333.
138. Young WF Jr, Stanson AW, Grant CS, Thompson GB, van Heerden JA. Primary aldosteronism: Adrenal venous sampling. Surgery. 1996;120:913-919; discussion 919-920.
139. Young WF Jr, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136:1227-1235.
140. Kempers MJ, Lenders JW, van Outheusden L, et al. Systematic review: Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151:329-337.
141. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf). 2009;70:14-17.
142. Young WF Jr. Primary aldosteronism-one picture is not worth a thousand words. Ann Intern Med. 2009;151:357-358.
143. Sutherland DJ, Ruse JL, laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 1966;95:1109-1119.
144. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-265.
145. Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med. 1992;116:813-820.
146. So A, Duffy DL, Gordon RD, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens. 2005;23:1477-1484.
147. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab. 2008;93:3117-3123.
148. Grant CS, Carpenter P, van Heerden JA, Hamberger B. Primary aldosteronism. Clinical management. Arch Surg. 1984;119:585-590.
149. Walz MK, Gwosdz R, Levin SL, et al. Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg. 2008;32:847-853.
150. Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM. Laparoscopic management of primary hyperaldosteronism: Clinical experience with 212 cases. J Urol. 2003;169:32-35.
151. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. JAMA. 1965;193:200-206.
152. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-896.
153. Gaddam K, Corros C, Pimenta E, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical study. Hypertension. 2010;55:1137-1142.
154. Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis. 2010;52:393-400.
155. Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in primary aldosteronism. Horm Metab Res. 2010;42:429-434.
156. Vogt B, Burnier M. Aldosterone and cardiovascular risk. Curr Hypertens Rep. 2009;11:450-455.
157. Sechil A, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009;94:1191-1197.
158. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
159. Catena C, Colussi G, lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911-918.
160. Born-Frontsberg E, Reincke M, Rump LC, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: Results of the German Conn's Registry. J Clin Endocrinol Metab. 2009;94:1125-1130.
161. Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009;94:869-875.
162. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90:5070-5076.
163. Catena C, Colussi G, Di Fabio A, et al. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res. 2010;42:440-445.
164. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens. 2001;19:353-361.